Literature DB >> 29859864

Clinical Risk Factors in Thrombolysis therapy: Telestroke Versus Nontelestroke.

Thomas I Nathaniel1, Jordan Gainey2, Brice Blum2, Chelsea Montgomery2, Lowther Ervin3, Lee Madeline3.   

Abstract

BACKGROUND: The objective of this study is to determine clinical risk factors associated with exclusion from thrombolysis in telestroke and nontelestroke settings. These risk factors may offer clues for optimization of thrombolysis therapy in acute ischemic stroke population.
MATERIALS AND METHODS: Retrospective data of patients with acute ischemic stroke via telestroke and nontelestroke assessment were analyzed. Univariate analysis was used to compare the recombinant tissue plasminogen activator (rtPA) group and the no rtPA group. A stepwise binary logistic regression identified factors associated with inclusion and exclusion from rtPA in the total telestroke population and the subsets of the telestroke population.
RESULTS: Telestroke patients were more likely to be directly admitted rather than being initially evaluated in the emergency department (70.3% versus 9.9%) and were also substantially more likely to receive rtPA (89.5% versus 38.5%). In the nontelestroke group, patients with acute ischemic stroke were more likely to be excluded from rtPA if they possessed higher international normalized ratios (odds ratio [OR] = 4.978 [1.503-16.488]) or had a history of congestive heart failure (OR = 2.524 [1.213-5.252]), previous stroke (OR = 2.172 [1.286-3.667]), or renal dysfunction (OR = 4.204 [1.33-13.281]). The telestroke group only had 1 variable deemed statistically significant in its association with rtPA status. Patients who were directly admitted were less likely to be excluded from receipt of rtPA (OR = .322 [.112-0.927]).
CONCLUSIONS: Factors associated with exclusion from rtPA in the nontelestroke setting did not exclude patients with acute ischemic stroke from thrombolysis therapy in the telestroke setting. Telestroke may offer methods for optimization of the risk-benefit ratio of rtPA, equipping clinicians to efficiently make treatment decisions.
Copyright © 2018 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute ischemic stroke; clinical risk factors; nontelestroke; recombinant tissue plasminogen activator (rtPA); telestroke

Mesh:

Substances:

Year:  2018        PMID: 29859864     DOI: 10.1016/j.jstrokecerebrovasdis.2018.05.012

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  11 in total

1.  Association of Financial Factors and Telemedicine Adoption for Heart Attack and Stroke Care Among Rural and Urban Hospitals: A Longitudinal Study.

Authors:  Amir Alishahi Tabriz; Kea Turner; Dunc Williams; Nimmy Babu; Steve North; Christopher M Shea
Journal:  Telemed J E Health       Date:  2021-09-24       Impact factor: 5.033

2.  Stroke Severity among Men and Women Acute Ischemic Stroke Patients in the Telestroke Network.

Authors:  Nicolas Poupore; Camron Edrissi; Mareshah Sowah; Madison Stanley; Jonah Joffe; Donovan Lewis; Teanda Cunningham; Carolyn Breauna Sanders; Krista Knisely; Chase Rathfoot; Thomas I Nathaniel
Journal:  Cerebrovasc Dis Extra       Date:  2022-06-08

3.  Gender differences in comorbidities and risk factors in ischemic stroke patients with a history of atrial fibrillation.

Authors:  Chase Rathfoot; Camron Edrissi; Carolyn Breauna Sanders; Krista Knisely; Nicolas Poupore; Thomas Nathaniel
Journal:  BMC Neurol       Date:  2021-05-25       Impact factor: 2.474

4.  The Association Between an Antecedent of Transient Ischemic Attack Prior to Onset of Stroke and Functional Ambulatory Outcome.

Authors:  Nicolas Poupore; Dan Strat; Tristan Mackey; Thomas I Nathaniel
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

5.  The telestroke and thrombolysis therapy in diabetic stroke patients.

Authors:  Thomas I Nathaniel; Chibueze Ubah; Leah Wormack; Jordan Gainey
Journal:  Diabetol Metab Syndr       Date:  2019-05-09       Impact factor: 3.320

6.  Gender and thrombolysis therapy in stroke patients with incidence of dyslipidemia.

Authors:  Brice Blum; Leah Wormack; Mason Holtel; Alexandria Penwell; Shyyon Lari; Brittany Walker; Thomas I Nathaniel
Journal:  BMC Womens Health       Date:  2019-01-16       Impact factor: 2.809

7.  In acute ischemic stroke patients with smoking incidence, are more women than men more likely to be included or excluded from thrombolysis therapy?

Authors:  Oluyemi R Rotimi; Iretioluwa F Ajani; Alexandria Penwell; Shyyon Lari; Brittany Walker; Thomas I Nathaniel
Journal:  Womens Health (Lond)       Date:  2020 Jan-Dec

8.  Ischemic stroke with a preceding Trans ischemic attack (TIA) less than 24 hours and thrombolytic therapy.

Authors:  Nicolas Poupore; Dan Strat; Tristan Mackey; Ashley Snell; Thomas Nathaniel
Journal:  BMC Neurol       Date:  2020-05-19       Impact factor: 2.474

9.  Effect of antihypertensive medications on thrombolysis therapy and outcomes in acute ischemic stroke patients.

Authors:  Tyler Fleming; Brice Blum; Benjamin Averkamp; James Sullivan; Thomas Nathaniel
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-01-23       Impact factor: 3.738

10.  Cholesterol reducer and thrombolytic therapy in acute ischemic stroke patients.

Authors:  Nicolas Poupore; Dan Strat; Tristan Mackey; Katherine Brown; Ashley Snell; Thomas I Nathaniel
Journal:  Lipids Health Dis       Date:  2020-05-06       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.